FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:460 August 17, 1995 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Barnett, H. J.M. Related Article by Barnett, H. J.M. PubMed Citation

To the Editor: Barnett et al. (Jan. 26 issue)¹ state that "neutropenia occurs early but is reversible after the cessation of [ticlopidine]." Unfortunately, this is not always true. Six patients who died of irreversible ticlopidine-induced bone marrow failure have been reported to the Canadian Health Protection Branch. In four of the patients (one man and three women; age, 70 to 86 years), agranulocytosis developed (granulocyte count, <500 per cubic millimeter) 15 to 74 days (mean, 38) after ticlopidine was begun. Two women, 72 and 84 years old, had aplastic anemia that first presented as agranulocytosis 27 and 41 days after . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Paradiso-Hardy, F. L., Angelo, C. M., Lanctot, K. L., Cohen, E. A. (2000). Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ 163: 1441-1448 [Abstract] [Full Text]  
• Barnett, H. J M, Eliasziw, M., Meldrum, H. E (1999). Evidence based cardiology: Prevention of ischaemic stroke. BMJ 318: 1539-1543 [Full Text]